<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33628588</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">2095-3941</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; medicine</Title>
          <ISOAbbreviation>Cancer Biol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>105</StartPage>
          <EndPage>119</EndPage>
          <MedlinePgn>105-119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.20892/j.issn.2095-3941.2020.0098</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">The oncoprotein, hepatitis B X-interacting protein (HBXIP), has been reported to play an important role in human malignancies. However, its functions in non-small cell lung cancer (NSCLC) are poorly understood. The goal of the present study was to identify the role of HBXIP in the regulation of NSCLC development.</AbstractText>
          <AbstractText Label="METHODS">The level of HBXIP expression in NSCLC tissue was assessed by immunohistochemical and Western blot analyses, and its relationships with clinicopathological features and outcomes were statistically evaluated. The effects of HBXIP on NSCLC cell progression were assessed through cell viability, colony formation, and flow cytometry analyses <i>in vitro</i>. The mechanism by which HBXIP regulated the MAPK pathway was studied by Western blot, immunofluorescence, and immunoprecipitation assays. In addition, <i>in vivo</i> experiments were performed to evaluate the progression of NSCLC and ERK signaling pathway activation after HBXIP knockdown.</AbstractText>
          <AbstractText Label="RESULTS">HBXIP was overexpressed in human NSCLC and was correlated with the invasiveness of NSCLC. The high expression of HBXIP in NSCLC was significantly correlated with gender (<i>P</i> = 0.033), N stage (<i>P</i> = 0.002), and tumor-node-metastasis stage (<i>P</i> = 0.008). <i>In vitro</i> experiments using an NSCLC cell line revealed that HBXIP knockdown resulted in the suppression of cell proliferation and colony formation, which was consistent with the enhanced cell cycle arrest in G1 phase. The results of a mechanistic investigation suggested that binding of HBXIP to MEK1 protein promoted MAPK/ERK signaling pathway activation in NSCLC by preventing the proteasome-mediated degradation of MEK1. In addition, the results obtained using <i>in vivo</i> subcutaneous tumor xenografts confirmed that HBXIP deficiency decreased MEK1 protein levels and NSCLC tumor growth.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Taken together, our results showed that the HBXIP-MEK interaction promoted oncogenesis <i>via</i> the MAPK/ERK pathway, which may serve as a novel therapeutic target for cancers in which MAPK/ERK signaling is a dominant feature.</AbstractText>
          <CopyrightInformation>Copyright: © 2021, Cancer Biology &amp; Medicine.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Bei</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Outpatient Office, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Xianhui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Xiukun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhi</LastName>
            <ForeName>Jingtai</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Xiangrui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiangqian</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-5545-119X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-2743-2247</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Med</MedlineTA>
        <NlmUniqueID>101588850</NlmUniqueID>
        <ISSNLinking>2095-3941</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C110719">LAMTOR5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.12.2</RegistryNumber>
          <NameOfSubstance UI="D048369">MAP Kinase Kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.12.2</RegistryNumber>
          <NameOfSubstance UI="C482125">MAP2K1 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048369" MajorTopicYN="N">MAP Kinase Kinase 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015513" MajorTopicYN="N">Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">HBXIP</Keyword>
        <Keyword MajorTopicYN="Y">MEK1</Keyword>
        <Keyword MajorTopicYN="Y">non-small cell lung cancer</Keyword>
        <Keyword MajorTopicYN="Y">tumor progression</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest statement No potential conflicts of interest are disclosed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33628588</ArticleId>
        <ArticleId IdType="pmc">PMC7877173</ArticleId>
        <ArticleId IdType="doi">10.20892/j.issn.2095-3941.2020.0098</ArticleId>
        <ArticleId IdType="pii">j.issn.2095-3941.2020.0098</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) CA Cancer J Clin. 2015;385:977–1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4588097</ArticleId>
            <ArticleId IdType="pubmed">25467588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, et al.  Cancer Statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26808342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26742998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23972814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26667336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felip E, et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:89–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23860613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winther-Larsen A, Nissen PH, Jakobsen KR, Demuth C, Sorensen BS, Meldgaard P. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. Lung Cancer. 2015;90:314–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26386832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 2005;8:381–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16286246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17496923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melegari M, Scaglioni PP, Wands JR. Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol. 1998;72:1737–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC109461</ArticleId>
            <ArticleId IdType="pubmed">9499022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Wang YX, Che SL, Yang Y, Piao JJ, Liu SP, et al.  HBXIP over expression as an independent biomarker for cervical cancer. Exp Mol Pathol. 2017;102:133–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28093193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li XG, Liu SP. Suppression of HBXIP reduces cell proliferation, migration and invasion in vitro, and tumorigenesis in vivo in human urothelial carcinoma of the bladder. Cancer Biother Radiopharm. 2016;31:311–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27831760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Fang RP, Cui M, Zhang WY, Bai X, Wang HW, et al.  The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer. Cancer Lett. 2017;385:234–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27765671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu FQ, Zhu XM, Han T, You XN, Liu FB, Ye LH, et al.  The oncoprotein hepatitis B X-interacting protein promotes the migration of ovarian cancer cells through the upregulation of S-phase kinase-associated protein 2 by Sp1. Int J Oncol. 2014;45:255–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24788380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Li H, Zhang YY, Li LL, Fang RP, Li YH, et al.  Oncoprotein HBXIP modulates abnormal lipid metabolism and growth of breast cancer cells by activating the LXRs/SREBP-1c/FAS signaling cascade. Cancer Res. 2016;76:4696–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26980761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, et al.  HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22:2729–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC156760</ArticleId>
            <ArticleId IdType="pubmed">12773388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujii R, Zhu CJ, Wen YF, Marusawa H, Bailly-Maitre B, Matsuzawa S, et al.  HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res. 2006;66:9099–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16982752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen YF, Golubkov VS, Strongin AY, Jiang W, Reed JC. Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem. 2008;283:2793–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18032378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Bai X, Li H, Zhang Y, Zhao Y, Zhang X, et al.  The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells. Int J Cancer. 2013;133:1310–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23494474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, Li L, Zhang Y, Zhang Y, Zhao Y, You X, et al.  The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J Biol Chem. 2012;287:30228–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3436276</ArticleId>
            <ArticleId IdType="pubmed">22740693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu F, You X, Liu F, Shen X, Yao Y, Ye L, et al.  The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells. Cancer Lett. 2013;333:124–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23352642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue L, Li L, Liu F, Hu N, Zhang W, Bai X, et al.  The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells. Carcinogenesis. 2013;34:927–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3616668</ArticleId>
            <ArticleId IdType="pubmed">23291272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell. 2012;150:1196–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3517996</ArticleId>
            <ArticleId IdType="pubmed">22980980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li XM, Ruan XH, Zhang PT, Yu Y, Gao M, Yuan SK, et al.  TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57(KIP2) repression. Oncogene. 2018;37:2773–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29511350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Araujo MEG, Naschberger A, Furnrohr BG, Stasyk T, Dunzendorfer-Matt T, Lechner S, et al.  Crystal structure of the human lysosomal mTORC1 scaffold complex and its impact on signaling. Science. 2017;358:377–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28935770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4320046</ArticleId>
            <ArticleId IdType="pubmed">24071851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandoth C, McLellan MD, Vandin F, Ye K, Niu BF, Lu C, et al.  Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3927368</ArticleId>
            <ArticleId IdType="pubmed">24132290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16557281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5461196</ArticleId>
            <ArticleId IdType="pubmed">28481359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med. 2016;374:1864–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27168435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al.  Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3311875</ArticleId>
            <ArticleId IdType="pubmed">22235099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3916180</ArticleId>
            <ArticleId IdType="pubmed">22327622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4175590</ArticleId>
            <ArticleId IdType="pubmed">25204415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuevas BD, Abell AN, Witowsky JA, Yujiri T, Johnson NL, Kesavan K, et al.  MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. EMBO J. 2003;22:3346–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC165646</ArticleId>
            <ArticleId IdType="pubmed">12839996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maruyama T, Kadowaki H, Okamoto N, Nagai A, Naguro I, Matsuzawa A, et al.  CHIP-dependent termination of MEKK2 regulates temporal ERK activation required for proper hyperosmotic response. EMBO J. 2010;29:2501–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2928693</ArticleId>
            <ArticleId IdType="pubmed">20588253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui WJ, Zhao Y, Shan CL, Kong GY, Hu N, Zhang YW, et al.  HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-kappa B signaling to protect breast cancer cells from complement attack. FEBS Lett. 2012;586:766–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22293503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YH, Zhang Z, Zhou XL, Li LL, Liu Q, Wang Z, et al.  The oncoprotein HBXIP enhances migration of breast cancer cells through increasing filopodia formation involving MEKK2/ERK1/2/Capn4 signaling. Cancer Lett. 2014;355:288–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25304384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nada S, Hondo A, Kasai A, Koike M, Saito K, Uchiyama Y, et al.  The novel lipid raft adaptor p18 controls endosome dynamics by anchoring the MEK-ERK pathway to late endosomes. EMBO J. 2009;28:477–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2657578</ArticleId>
            <ArticleId IdType="pubmed">19177150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nada S, Mori S, Takahashi Y, Okada M. p18/LAMTOR1: a late Endosome/Lysosome-Specific anchor protein for the mTORC1/MAPK signaling pathway. Methods Enzymol. 2014;535:249–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24377928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teis D, Wunderlich W, Huber LA. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell. 2002;3:803–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12479806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teis D, Taub N, Kurzbauer R, Hilber D, de Araujo ME, Erlacher M, et al.  p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol. 2006;175:861–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2064696</ArticleId>
            <ArticleId IdType="pubmed">17178906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teis D, Huber LA. The odd couple: signal transduction and endocytosis. Cell Mol Life Sci. 2003;60:2020–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14618253</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
